Attention Guest: Please make sure that you are using a unique password to login to MESO. If you have used your MESO password on another website, change it immediately. You should NEVER share the same login credentials on multiple websites.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Discussion in 'Men's Economics' started by Michael Scally MD, Dec 12, 2012.

  1. Michael Scally MD

    Michael Scally MD Doctor of Medicine

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
    Acadia Pharmaceuticals
    ACADIA Pharmaceuticals Inc.: NASDAQ:ACAD quotes & news - Google Finance


    ACADIA Announces Pimavanserin Meets Primary and Key Secondary Endpoints in Pivotal Phase III Parkinson’s Disease Psychosis Trial
    Pimavanserin Demonstrates Highly Significant Antipsychotic Efficacy and Maintenance of Motor Control in Parkinson’s Patients
    Significant Improvements Also Observed in All Secondary and Exploratory Measures
    Acadia Pharmaceuticals - Investor Relations -News Release


    ACADIA Pharmaceuticals Conference Call to Present Top-line Results from its Pivotal Phase III Pimavanserin Parkinson's Disease Psychosis Trial
    Acadia Pharmaceuticals - Investor Relations -Event Details


    Acadia’s Value Heavily Dependent On Pimavanserin Data
    Acadia's Value Heavily Dependent On Pimavanserin Data

    In the past we’ve written extensively on the redesigns management has instituted in the -020 trial versus the failed -012 and -014 studies. Our article from January 2012, “Will Third Time Be A Charm For Acadia Pharmaceuticals?” provides a good analysis of these changes.


    ACADIA Pharmaceuticals Announces $86 Million Equity Financing
    --Proceeds to Support Completion of Pimavanserin Phase III Program--
    Acadia Pharmaceuticals - Investor Relations -News Release